Investors
Bioxodes is a Belgian private clinical stage company, founded in 2013. The Company has received fundings from both public and private investors and is now looking for Series B funding.
video testimonial
Watch our CEO Marc Dechamps present Bioxodes to investors in Zurich
with support from world-renowned stroke expert Prof Robin Lemmens, head of the stroke unit at the University Hospital Leuven (Belgium), and Hans Warrinnier, Bioxodes' Chief Medical Officer.
Investors
Public & private investors
Private Equity
(Euros)
Grants/subsidies from the Walloon Region
(Euros)
Investors
Who invests?
Investors
Why invest?
-
First-in-class lead compound with solid preclinical and Phase 1 clinical data, now supported by compelling interim data from the ongoing Phase 2a trial in intracerebral hemorrhage (ICH).
-
Discovery program for innovative pipeline to extend value capture beyond thrombo-inflammation.
-
Leadership and expertise with international advisor network.
-
Patent portfolio wholly owned with coverage beyond 2040.
Investors
Invest in us
Get in touch and explore our investment opportunities
investment@bioxodes.com